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INTRODUCTION 
Subsequent breakthroughs in oncology, including the use of more effective local and 
systemic treatment strategies have meaningfully improved patient outcomes for many 
cancer types, in particular when the tumour is still restricted to the primary site. 
However, despite these advances this outlook changes drastically when metastases 
develop. Bone metastases still are a common feature of advanced cancer such as 
lung, breast and prostate cancer, and remain generally incurable. 
In this review we summarize the major mechanisms that drive physiological bone 
remodeling and metastatic bone disease from a molecular biology point of view 
highlighting the key pathways involved in these processes as we understand them 
today. In addition to these mechanistic insights, we evaluate the available clinical 
evidence for agents that target the discussed pathways. 
THE VICIOUS CYCLE OF BONE METASTASIS 
Bone is constantly being formed, broken down and renewed, with two specialized cell 
lines intricately working together to regulate and maintain bone mass. The osteoclast, 
which is derived from a hematopoietic lineage of cells, resorbs bone, while the 
osteoblast, whose origin is mesenchymal, synthesizes bone matrix.[1] The balance 
between the activity of both cell types is of extreme importance to maintain functional 
and healthy bone. Overactivation of osteoclasts results in fragile and brittle bone (e.g. 
osteoporosis), while lack of osteoclast function causes high bone density (e.g. 
osteopetrosis). 
Bone resorption starts with the differentiation of osteoclastic hematopoietic precursors 
to mature osteoclasts that attach to the bone matrix. Podosomes, which contain actin 
and gVく3 integrin, facilitate this adhesion and form a connection with the proteins 
osteopontin and vitronectin of the bone matrix. The Howship’s lacuna is the region 
where bone resorption occurs and is closed-off where the cell adheres to bone, called 
the clear zones.[2] The resorptive surface of the osteoclasts excretes enzymes which 
digest the organic bone matrix (mostly consisting of collagen) and acidify the 
environment to dissolve the inorganic compound (hydroxyapatite) to phosphate, 
calcium and water. This acidic milieu is created by osteoclast expressed carbonic 
anhydrase 2 enzyme, which is present in the cytoplasm of the cell and generates 
H2CO3 from H2O and CO2. The spontaneous dissociation of carbonic acid results in 
the generation of a proton (H+) and bicarbonate (HCO3-). While the proton is excreted 
at the resorptive surface by proton pump activity (H+-ATPase), electroneutrality is 
preserved by a chloride channel that releases the bicarbonate on the basolateral 
membrane of the osteoclast preventing excess of bicarbonate to act as a limiting factor 
for the chemical reaction.[3] 
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Together with the dissolution of the inorganic bone matrix, the organic part of the bone 
is digested by the enzyme cathepsin K, which is a cysteine protease that targets the 
abundance of cysteine residues present in the structure of collagen. The primary 
degradation products of collagen are subsequently enclosed in vesicles containing the 
enzyme tartrate-resistant acid phosphatase (TRAP) which facilitates further 
degradation. These vesicles are then transported through the cytoplasm of the cell 
and released on the basolateral side.[4, 5] 
The physiological process of bone resorption by osteoclasts is then followed by new 
bone formation by osteoblasts. When the bone microenvironment is invaded by 
metastatic tumourcells, this tightly controlled remodeling process becomes severely 
disturbed. The resulting dysregulation of bone homeostasis is termed the “vicious 
cycle” and starts with the secretion by the invading tumourcells of numerous proteins 
in the bone microenvironment (most importantly parathyroid hormone-related protein 
[PTHrP]) that promote osteoclast function and thus bone degradation. In addition, 
these growth factors will not only increase the recruitment, differentiation and 
activation of osteoclasts and osteoblasts, but will also severely disrupt the critical 
feedback mechanisms between these cells. The result is a positive feedback 
mechanism allowing tumourcells to proliferate by the release of growth factors and 
ionized calcium as result of excessive bone resorption by osteoclasts. In addition to 
tumourprogression, this process frequently exposes the patient to pain and bone 
complications such as fracture, spinal cord compression, and hypercalcemia. In 
reality, the vicious cycle consists of a vastly more complex network of mediators and 
interactions, with several drugs currently available that successfully target osteoclast 
formation and function to interrupt the vicious cycle and decrease skeletal 
complications in patients with metastatic bone disease as detailed in the following 
paragraphs.[6, 7] 
PHARMACOLOGICAL TARGETS OF OSTEOCLAST FUNCTION 
An overview of the discussed osteoclast targets is presented in Figure 2. 
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Figure 2: Summary of actionable targets in osteoclasts to inhibit bone resorption. (Figures creative commons attribution 3.0) 
Bisphosphonates 
Mechanism of action 
Bisphosphonates were the first class of drugs that could successfully inhibit bone 
resorption by selective inhibition of osteoclasts, as first published by Herbert Fleisch[8] 
50 years ago when they were still (incorrectly) referred to as diphosphonates. Two 
classes have subsequently been developed, with the older bisphosphonates (such as 
etidronate and clodronate) acting by reversing the pyrophosphorylytic reactions which 
are catalysed by aminoacyl-tRNA synthetases. This results in the generation of toxic 
non-hydrolysable bisphosphonate analogues of ATP (AppCp) which inhibit 
mitochondrial ADP/ATP translocase and induce osteoclast apoptosis.[9] However due 
to their low potency they have been superseded in clinical practice by newer 
generation bisphosphonates. Indeed, the current day clinically used nitrogen-
containing bisphosphonates (N-BP) (e.g. pamidronate, risedronate, zoledronate) 
target the osteoclast farnesyl pyrophosphate synthetase (FPPS) and geranylgeranyl 
pyrophosphate synthase (GGPPS).[10] Once administered the N-BP, which has a 
high affinity for Ca2+ due to the two phosphonate groups, rapidly localizes to the bone 
mineral. When osteoclasts start resorbing this bisphosphonate saturated bone, the low 
pH in the Howship’s lacuna protonates the phosphonate groups of the N-BP, releasing 
the N-BP from the bone mineral and dissolving them. The free bisphosphonate is then 
captured in vesicles and enters the osteoclast by pinocytosis. From the internalized 
vesicles the N-BP enters the cytosol after further protonation. In normal conditions 
FPPS and GGPPS, which are part of the mevalonate pathway, generate FPP and 
GPP. Both these compounds are important in the production of isoprenoids, which are 
lipids that are crucial for the post-translational prenylation of GTPases such as Ras 
and Rho. In addition, the accumulation of the substrates generates ApppI, a cytotoxic 
ATP analogue.[11] The N-BP however binds to the pocket of the FPPS enzyme and 
induces a conformational change, inhibiting the prenylation of GTPases and altering 
their intracellular localization and function.[12] While the mevalonate pathway is 
present in all cells of the human body, N-BP mainly affect osteoclasts because of their 
high affinity for bone mineral and the high endocytic activity of osteoclasts.[13, 14] The 
local effect of bisphosphonates in the microenvironment can be prolonged, as these 
molecules can reattach to the bone after dissolution.[15] 
Effect of bisphosphonates on tumourgrowth 
Next to the effect on osteoclasts, multiple preclinical studies and some clinical trials 
have demonstrated the positive effect of N-BP administration on the incidence of bone 
metastases and tumour progression in bone.[16] Taken together, evidence suggests 
the existence of direct and indirect anti-tumour effects of bisphosphonates and other 
bone modifying agents (Figure 1). First, indirect effects act through the inhibition of 
bone resorption which reduces the release and local availability of tumour growth 
factors (e.g. TGF-く) from bone matrix, interrupting the vicious cycle and making bone 
a less attractive environment for tumour cells.[16, 17] In addition, compelling in vivo 
data has demonstrated the direct targeting by N-BPs of cancer promoting pathways, 
including angiogenesis. This is mediated by inhibition of FPPS activity which disturbs 
prenylation signalling and leads to inhibition of endothelial cell adhesion, survival and 
migration.[16] N-BPs are also taken up by monocytes and dendritic cells, where 
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inhibition of the mevalonate pathway triggers elevated levels of the phosphor-antigen 
IPP, which is a strong activator of a specific subset of T lymphocytes (けh T cells).[18] 
Together with presentation of the IPP antigen by cancer cells, the subsequent 
activation of けh T cells leads to the release of interferon-け and perforin, and cytotoxic 
tumour cell death. This immune system activating action of bisphosphonates has also 
been postulated to explain the flu-like symptoms that patients may experience after 
administration of these agents. 
Next, preclinical data have also showed decreased tumour growth in bone in 
osteoclast deficient mice, suggesting a direct anti-tumour effect of N-BPs.[19] Further 
evidence for a direct anti-tumour effect comes from the observation that the 
administration of the highly bone-seeking phosphonocarboxylate analogue of 
risedronate resulted in reduced skeletal tumour growth even at doses that did not 
inhibit osteolysis.[20, 21] Furthermore, apoptosis was observed in a xenograft model 
of myeloma treated with clinically relevant doses of the N-BP zoledronic acid, where 
the presence of unprenylated Rap1A provided strong mechanistic evidence of 
inhibition of FPPS by zoledronic acid in these non-skeletal tumours.[22] Finally, tumour 
cell migration and invasion are also susceptible to N-BPs, with preliminary studies 
showing inhibited cellular invasion, which reduces metastatic outgrowth.[16] 
 
Figure 1: Direct and indirect effects of bone modifying agents in the bone tumour microenvironment. While indirect inhibition of 
tumour growth is mainly attributed to the interruption of the vicious cycle of bone resorption and growth factor release, direct 
anti-tumour effects through multiple mechanisms have been described for specific agents, including bisphosphonates (BP) (in 
particular zoledronic acid [Z]) and denosumab (D). (Figures creative commons attribution 3.0) 
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Receptor activator of nuclear factor-kB ligand (RANKL) inhibitors 
Mechanism of action 
The receptor activator of nuclear factor-kB ligand (RANKL) is a type 2 transmembrane 
protein from the TNF superfamily that exists in a membrane bound and soluble form 
that are both bioactive. The soluble form is generated by proteolytic cleavage of the 
membrane bound protein. In bone, RANKL is found on stromal/osteoblastic cells or 
exists in soluble form. It promotes the differentiation of osteoclastic precursor cells, 
activates mature osteoclasts and it prolongs osteoclast cell survival. The RANKL 
antagonist denosumab binds with high affinity to RANKL and blocks the binding with 
the RANK receptor and further downstream signaling. Osteoprotegerin (OPG) is the 
naturally occurring soluble decoy receptor for RANKL and binding with OPG results 
inhibition of RANKL-RANK signaling.[23] 
Effect of RANKL inhibition on tumourgrowth 
Preclinical studies have shown that RANKL-RANK inhibition reduces tumour-induced 
bone lesions, both those with osteolytic, osteoblastic or mixed phenotypes. This 
supports the notion that osteoclastic activity is a requisite element for osteolytic and 
osteoblastic lesions. Preclinical studies showed an important effect in tumour growth 
reduction as a consequence of interrupting the vicious cycle. Also, additive effects are 
observed when RANKL blockade is administered together with other therapies.[24] 
More recently, the complex interplay of RANK/RANKL signalling and 
tumourimmunology has generated a lot of interest. In particular, RANKL may be 
involved in another vicious cycle that involves Treg lymphocytes and tumourassociated 
macrophages (TAMS) that have a high RANK expression and in which RANKL can 
act as a chemoattractant for these cells. Conditional on other factors, both TAMS and 
Tregs have the potential to promote tissue invasion and metastasis, and enhance the 
tumourpermissive properties of macrophages through RANK/RANKL signalling. The 
use of RANKL-targeted agents such as denosumab may therefore be a promising 
adjunct treatment strategy, especially in novel cancer immunotherapies.[25] 
mTOR inhibitors 
Mechanism of action 
Phosphoinositide 3-kinase (PI3K) is an important pathway in different malignancies 
and dysregulation of the PI3K/AKT/mTOR pathway is a frequent observation in 
cancer.[26] Initiation of this pathway occurs through activation of receptor tyrosine 
kinases (RTK) by growth factors. In cancer cells upregulation or mutation of the RTK 
and/or their subunits p110g, p110く, p85g, p85く can occur. Additional activation is 
observed through the internal RAS and AKT (protein kinase B) pathway, whereas 
negative feedback mechanisms via PTEN and the TSC complex are frequently lost in 
malignancies. An important drug target in this pathway is the mechanistic target of 
rapamycin (mTOR), whose inhibition leads to a marked reduction in protein synthesis 
and cell growth. Two protein complexes of mTOR have been described (mTORC1 and 
mTORC2), and compounds that inhibit both complexes achieve superior inhibition of 
cell survival, proliferation and metabolism, compared to single complex inhibition 
alone, in preclinical studies.[27] 
Working on a different target in the pathway are PI3K specific inhibitors, which can act 
on all or a specific subset of isoforms of PI3K. Normal activation of the PI3K pathway, 
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results in the activation of the RAS and AKT pathway promoting cell growth, 
differentiation, survival, proliferation and metabolism. The more specific inhibitors 
have a more narrow activity profile, a limitation that may be overcome by strict patient 
selection based on the analysis of mutational characteristics of the primary tumouror 
its metastases. 
Compounds with both mTORC1/2 and PI3K inhibition have been generated as well, 
as these targets share structural domains belonging to the PI3K-related kinases 
superfamily (PIKK). This results in upstream and downstream AKT inhibition, avoiding 
the negative feedback activation loop, but at the cost of higher toxicity. 
Drugs targeting AKT seem to be an interesting approach for tumourcells with loss of 
function mutations in the tumoursuppressor PTEN, as PTEN is a downstream complex 
of PI3K required for signaling of the AKT target.[27] 
Effect of the mTOR inhibitor everolimus on bone 
The effect of the mTOR inhibitor everolimus on osteoclastic and osteoblastic cells was 
evaluated in vitro. Osteoclastic precursor cells showed decreased cell viability with 
increasing everolimus concentrations, but more pronounced negative effects were 
observed on osteoclast formation and in mature osteoclasts. In human osteoblastic 
precursor cells the activity also decreased with incubation with everolimus. These 
findings established the importance of the mTOR pathway in bone biology. 
Interestingly, the RANK-RANKL signaling pathway for activating osteoclasts acts 
through mTOR signaling. This is supported by the observation that incubation with 
rapamycin, another mTOR inhibitor, results in an increase in OPG, an important decoy 
receptor for RANKL.[28, 29]  
Preclinical in vivo experiments with everolimus in a murine ovariectomized model 
showed an increase in bone mineral density by 38%, and of total calculated bone 
volume by 37% in comparison with a control group. These results were confirmed by 
measurement of increased trabecular number and decreased trabecular separation. 
Additional histomorphology results showed a decrease in osteoclastic cell numbers by 
25% with treatment. Everolimus could even partly reverse the bone remodeling rate 
by 41.5% in the same murine models. When a preclinical model of bone metastases 
was used, everolimus reduced bone lesions by 45%, increased bone mineral density 
and bone formation rate >50%, and decreased the total number of osteoclasts 
43%.[30] All these data indicate a bone protective effect of everolimus. 
MET and VEGFR2 inhibitors 
Mechanism of action 
Cabozantinib, a tyrosine kinase inhibitor (TKI), inhibits the phosphorylation of the 
tyrosine kinase receptors of mostly MET and VEGFR2, but also that of other receptors 
from the same family. The hepatocyte growth factor (HGF) is the only known ligand 
for the MET receptor and this signaling pathway is frequently dysregulated in different 
tumourtypes. Overexpression of both MET and VEGFR2 has been shown to induce 
metastases and tumorigenesis.[31] 
While treatment with selective VEGFR inhibitors has demonstrated superior clinical 
outcomes, tumourrelapse or progression invariable occurs after some time.[32] The 
7 
 
resistance mechanism to the VEGFR inhibitor treatment is possibly upregulation of 
tyrosine kinase receptors (MET and VEGFR) caused by treatment induced hypoxia. 
In addition crosstalk between different pathways exist, providing the rationale for the 
development of TKIs with dual or broad spectrum activity. 
In bone, treatment of osteoclasts with HGF results in increased cytosolic Ca2+ and Src 
kinase activity, both crucial for regulating the activity of osteoclasts. However, the 
increase in cell activity is not specific to osteoclasts and could be seen in other cell 
lines as well (epithelial cells, fibroblasts). In vitro motility experiments showed 
increased motility (chemotactic migration) of osteoclasts measured by the number of 
osteoclastic cells crossing a collagen filter. Increased DNA replication was observed 
as well after stimulation with HGF and osteoclasts are able to secrete HGF 
themselves. The only effect observed on osteoblastic cells was stimulation of the DNA 
synthesis.[33-35] 
Effect of cabozantinib on bone metastases 
Preclinical studies with cabozantinib in prostate cancer models have shown a better 
effect on osteoblastic metastases compared to osteolytic lesions. In particular 
cabozantinib reduced the size of osteoblastic lesions and reduced bone remodelling 
at the site of bone metastases. The effect of cabozantinib on osteoblast is biphasic, 
with induction of early osteoblast differentiation at low doses, and inhibition of 
osteoblast differentiation at higher doses, which may be due to the overall impact of 
cabozantinib on osteoblast viability. The reduction in bone resorption observed with 
cabozantinib treatment is primarily the result of a reduction in the numbers of 
osteoclasts, as opposed to the inhibition of the activity of individual mature 
osteoclasts.[35] 
Cathepsin K inhibitors 
Mechanism of action 
Cathepsin K, mentioned above, is an enzyme that breaks down the organic phase of 
bone. Inhibitors of cathepsin K interfere with the catalytic characteristics of the enzyme 
due to covalent binding with amino acids of the functional region of the enzyme. 
Cathepsin K has been suggested to not only inhibit bone resorption but also stimulate 
bone formation by reducing the degradation of growth factors.[36] Unfortunately, 
concerns about off-target inhibition of cathepsins are rising and have led to the 
withdrawal of one such inhibitor in a phase 3 clinical trial due to skin adverse 
effects.[37] 
Effect of cathepsin K inhibition on bone metastases 
Preclinical in vivo metastatic breast cancer models show reduced osteolytic bone 
lesion formation and progression, resulting in less bone destruction with the 
administration of a cathepsin K inhibitor. Breast cancer cells express cathepsin K 
which feeds the seed and soil mechanism of the metastases theory. However the 
overall antitumoureffect is dominantly due to the drug’s antiresorptive effect. This 
hypothesis was confirmed since no effect was seen on soft tissue breast cancer 
tumours.[38] 
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Src inhibitors 
Src is a non-receptor tyrosine kinase that is expressed in all tissue cells, yet the effect 
of src knockout in mice was only evident by the osteopetrotic phenotype in bone, due 
to the lack of osteoclast activity.[39] Not only do osteoclasts fail to form their functional 
resorptive membrane, but they also failed to migrate to the bone.[40] 
c-Src is involved in numerous osteoclast functions, it is important in the assembly and 
disassembly of the podosomes, which are crucial for the attachment of mature 
osteoclasts to the resorptive surface of the bone.[41] Src is also an important product 
in the signalling cascade of RANK-RANKL, with a defect or absence in Src resulting 
in an interrupted pathway.[42] An additional mechanism of action in osteoclasts is the 
secretion of proteases and the regulation of vesicle transport. Importantly, other non-
receptor kinases cannot replace the function of c-Src when it is lacking, highlighting 
its pivotal role in osteoclasts.[43] 
Leucine rich repeat containing G-protein coupled receptor 4 (LGR4) 
The leucine rich repeat containing G-protein coupled receptor 4 (LGR4) was identified 
as a new receptor for RANKL. RANKL was already known as the sole ligand of the 
RANK receptor and induces osteoclast synthesis and function, as discussed 
previously. 
LGR4 competes with RANK for binding RANKL, and inhibits osteoclast differentiation 
by suppressing RANK-TRAF6 signalling and activating Ggq Ca2+ induced inhibition of 
NFATC1 during osteoclastogenesis. Moreover, osteoclast apoptosis is induced 
through Fas expression, effectively making LGR4 a key negative feedback mechanism 
in the RANK-RANKL signalling pathway that negatively regulates osteoclast 
differentiation and bone resorption.[44] 
Dock5 inhibitors 
Dock5 is a protein that is involved in intracellular signalling networks and acts as 
activator of small G proteins. The Dock5 inhibitor C21 inhibits the nucleotide guanine 
exchange on GTPase Rac1, predominantly by blocking the DHR2 catalytic and 
dimerization domain. Rac1 is needed for the formation of the osteoclast sealing zone 
and inhibition leads to a malfunction in the attachment of the osteoclast to the bone 
matrix.[45] 
Preclinical in vivo data showed no impairment of bone formation with the use of C21 
in contrast to bisphosphonate treatment. Also, in models of bone metastatic cancer a 
reduced tumour burden in the bone and increased bone volume was demonstrated. 
Again, these effects can be largely attributed to the shutdown of the vicious cycle in 
the bone. C21 has potential for clinical use in osteoporosis and rheumatoid arthritis as 
well, as benefits in bone volume could be seen in specific models for these 
conditions.[46]  
PHARMACOLOGICAL TARG ETS OF OSTEOBLAST FUNCT ION 
An overview of the discussed osteoblast targets is presented in Figure 3. 
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Figure 3: Summary of actionable targets in osteoblasts to promote bone formation. (Figures creative commons attribution 3.0) 
Wnt inhibitors 
Mechanism of action 
The Wnt (Wingless-related integration site) pathway typically mediates close-range 
signalling between cells involving numerous processes in the body, including tissue 
shaping, proliferation, and metabolism. Signalling can occur through a canonical Wnt 
pathway (く-catenin dependent) or a non-canonical Wnt pathway (く-catenin 
independent). Activation of the く-catenin dependent pathway, by binding of Wnts to 
the Frizzled (FZD) receptors and the low density lipoprotein receptor related protein 
5/6 (LRP5/6) coreceptors, results in the recruitment of dishevelled proteins (Dv1). This 
suppresses the く-catenin destruction complex and the stabilized く-catenin 
subsequently enters the cell nucleus. After binding to the TCF (T-cell factor) / LEF 
(lymphoid enhancer factor) transcription factor coactivator, the transcription of Wnt 
genes is initiated. The non-canonical pathway results in the activation of: Wnt/mTOR 
(as described above), Wnt/STOP (stabilization of proteins, resulting in activation of 
cellular processes), Wnt/JNK (leading to transcriptional activation), Wnt/PCP 
(important in alignment of cell polarity across the tissue), Wnt/Ca2+(activation of 
canonical pathway or direct effect on transcription of Wnt genes) and Wnt/YAP/TAZ 
(activating transcription of Wnt genes). 
Importantly, the Wnt pathway contributes to physiological bone mass regulation as 
well as many processes related to bone metastases (primary tumour dissemination, 
metastatic tumour dormancy, metastatic tumour outgrowth, tumour induced 
osteogenesis and tumour induced osteolysis). In the bone microenvironment the 
effects of Wnt on osteoblast function dominate, yet are complex and mediated via both 
canonical and non-canonical Wnt signalling. Activation of the Wnt pathway leads to 
bone formation, but the relative contribution of the canonical and non-canonical 
pathways to bone formation needs to be further elucidated. In contrast, in osteoclasts 
canonical signaling can either promote or inhibit osteoclast differentiation depending 
on the type of Wnt that serves as pathway activator, illustrating the complexity of the 
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role of Wnts in bone and their potential role as target for therapeutic intervention.[47-
49] 
Regulation of the Wnt pathway 
The endogenous Wnt inhibitors Dickkopf-1 protein (DKK-1) and Sclerostin (SOST) 
bind to the LRP5/6 coreceptor preventing further signalling. While this coreceptor is 
predominantly present in canonical pathways, it also has importance in some non-
canonical signalling. Secreted frizzled-related proteins (SFR) and Wnt inhibitory factor 
1 (WIF1) bind directly to the Wnts, preventing binding of the ligand with the Wnt 
receptor. Both canonical and non-canonical pathways can be inhibited in this way. 
Effect of DKK-1 and SOST on bone metastases 
In preclinical models of metastatic breast cancer, DKK-1 can inhibit the growth of lung 
metastases. However, it also results in a 10-fold increase in the occurrence of bone 
metastases, without affecting primary tumour growth. This illustrates the dual role of 
DKK-1 in the breast cancer metastatic process. A possible mechanism may involve 
inhibition of Wnt/く-catenin signalling in osteoblasts resulting in a reduction of OPG 
secretion, the decoy receptor for RANKL. Without this decoy receptor RANKL can bind 
to RANK in an uninhibited way, resulting in uncontrolled bone resorption due to 
increased osteoclast differentiation and function.[50] 
Sclerostin (SOST) expression occurs only on osteocytes and interfering with SOST 
produces effects that are limited to bone and does not affect tumour proliferation. 
Treatment with an anti-sclerostin antibody in a mouse model of multiple myeloma 
prevented myeloma induced bone loss, reduced osteolytic lesions, and increased 
bone strength and resistance to fracture. Furthermore, the use of the anti-sclerostin 
antibody showed a superior increase in bone strength in comparison to zoledronic 
acid.[51] 
Endothelin inhibitors 
Mechanism of action 
The endothelin family consists of the small peptides ET-1, ET-2 and ET-3 (21 amino 
acids). ET-1 and ET-2 bind to the ETA and ETB receptor, while ET-3 only binds to the 
ETB receptor. An increased expression of ET-1 and ETA has been identified in renal, 
cervical, colon, lung, prostate, and ovarian tumours. Overall, activation of the ET 
pathway in cancer cells promotes tumour growth and progression, metastases, 
angiogenesis and proliferation. In the bone microenvironment the activation of ET-1/ 
ETA results in increased osteoblast numbers and function, and a reduction in 
osteoclast activation and motility, which results in matrix remodelling and bone 
deposition.[52] 
Effect of ETA antagonists on bone metastases 
Preclinical in vivo data showed reduced osteoblastic bone metastases with treatment 
of an ETA antagonist, but no effects on osteolytic lesion inducing cancers were 
observed.[52] The effect of the ETA antagonist zibotentan on overall survival was 
evaluated in a randomized controlled phase 3 trial (n=594) enrolling men with 
castration-resistant prostate cancer and bone metastases who were pain-free or mildly 
symptomatic for pain. Disappointingly, no benefit on overall survival or any secondary 
endpoints was observed in this study.[53]  
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THE EMERGING FIELD OF INNATE OSTEO-IMMUNITY AND BONE METASTASIS 
The clinical observation of the sometimes long interval (up to decades) between  
primary cancer diagnosis and the occurrence of bone metastases has since long 
strengthened the hypothesis that disseminated tumourcells (DTC) can remain 
dormant in the bone microenvironment by means of complex interactions with the local 
host. The role of the innate immune system in this process has been intensively 
studied over the last years and these efforts may pave the way for effective immune 
therapies that harbor the power of the patient’s own immune system to identify and 
clear DTCs or even bone metastases. However, current immunotherapies have only 
shown limited efficacy in bone probably because of low tumourimmunogenicity and 
tumourinduced tolerance, illustrating the need for a deeper understanding of local 
immune interactions in bone.[54-56] 
Role of osteoblasts in tumour promotion 
Intriguingly, some tumors can impact bone even without the presence of metastases. 
Two different in vivo mouse models of lung cancer showed increased osteoclast 
activity in different locations in the bones, without the presence of any metastases.[57] 
Further experiments also showed an increase in the number and activity of osteoblasts 
and neutrophils infiltrating the tumor. This was dependent on osteocalcin positive 
osteoblasts (Ocn+) and indicates an effect of osteoblasts on the tumor. Of note, these 
neutrophils were SiglecFhigh (sialic acid binding immunoglobulin like lectin F) positive 
and express genes that promote amongst others angiogenesis, extracellular matrix 
remodeling, suppression of T-cell responses, tumourcell proliferation and growth.[57] 
Immune checkpoints in cancer immunotherapy 
The activation of T-cells requires two stimulatory signals: tumour antigen presentation 
by dendritic cells or macrophages, and co-stimulatory CD28 signalling on the T-cell 
surface by the antigen presenting cell through the CD80-86 receptors (Figure 4).[58] 
However, delivering the actual immune response after activation of the T-cell can be 
severely hampered by difficulties in infiltrating the site of bone metastasis. In addition, 
inhibitory cells trigger pathways after T-cell activation that can abrogate an effective 
anti-tumourimmune response. For example, upregulated CTLA-4 can bind with CD80-
86 with a higher affinity than CD28 due to homologous resemblance, preventing the 
co-stimulatory signal.[59] Similarly, PD-1 is another immune checkpoint molecule that 
prevents over-action of the immune system by inducing apoptosis in the cells when it 
is activated by binding of its ligand. It is well-known that the PD-1 ligand is expressed 
by many cancer types and represents an important resistance pathway of tumour cells 
to immune mediated death. The recent clinical success of checkpoint inhibitor therapy 
in metastatic cancers (e.g. melanoma) using antibodies directed against CTLA-4 (e.g. 
ipilimumab) and PD-1 (e.g. pembrolizumab, nivolumab) receptors have showed the 
feasibility of these therapeutic approaches. Unfortunately not all patients will respond 
and responses are not always durable, suggesting that many other regulatory and 
escape pathways must exist. For this reason, combining multiple agents that target 
different checkpoints or pathways appears an attractive strategy to overcome 
resistance.[60] 
For example, the anti-RANKL and anti-CTLA-4 antibodies have modest anti-
metastatic effect when administered alone, but recent preclinical data suggests that 
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RANKL blockade improves the efficacy of anti-CTLA-4 antibodies against solid 
tumours and experimental metastases.[61] The same group also reported that RANKL 
blockade increases the anti-metastatic activity of antibodies targeting PD-1/PD-L1 in 
mouse models of melanoma, prostate and colon cancer.[62] While further clinical 
studies are required, a published case report of a woman with widespread bone 
metastatic melanoma achieving a remarkable response lasting 48 weeks with the 
combination treatment with denosumab (120 mg/ 4 weeks) and ipilimumab (3 mg/kg/ 
3 weeks) appears to support these findings.[63] 
 
Figure 4: Overview of the complex interactions between immune cells, osteoblasts, osteoclasts, and tumour cells in the bone 
microenvironment and the targets for immunotherapies in cancer treatment. (Figures creative commons attribution 3.0) 
TARGETING THE BONE MATRIX AND THE MICROENVIRONMENT 
Nerve growth factor (NGF) 
Bone pain is a common symptom in advanced cancer and can be challenging to treat. 
The nerve growth factor (NGF) is a member of the neurotrophin family and is important 
in the survival and maintenance of sensory and sympathetic neurons. The main 
receptor is tropomyosin receptor kinase A (TrkA) and binding of the ligand activates 
further intracellular signaling pathways.[64] Immunohistochemical analysis has 
demonstrated expression of the TrkA receptor by the majority of sensory and 
sympathetic nerve fibers in the bone environment and therefore makes it a potential 
target for treating bone pain.[64] 
Indeed, in vivo preclinical breast cancer models have shown a significant reduction in 
induced pain and sprouting of TrkA+ and GAP43+ nerves after administration of an 
anti-NGF antibody, while normal nerve morphology was maintained. However, 
treatment with anti-NGF therapy did not impact disease progression or tumour induced 
bone remodelling.[65] 
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Transforming growth factor く (TGFく) 
TGFく (transforming growth factor く) is important in the normal regulation of bone 
remodeling and maintains the balance between osteoblastic and osteoclastic activity. 
Cancer induced osteoclastic activity releases TGFく in the bone environment which 
promotes the vicious cycle of tumor-induced bone destruction. It has been shown that 
increased concentrations of TGFく are associated with poor disease prognosis, 
suggesting that targeting TGFく may improve outcome.[7] 
In preclinical mouse breast cancer models a decrease in tumour burden was observed 
in animals treated with an anti-TGFく antibody. Furthermore, a reduction in osteoclast 
activity, osteolytic lesions and levels of PTHrP (parathyroid hormone related peptide) 
were observed as well. In contrast, the number of osteoblasts increased during 
treatment, supporting the ability of this treatment to abrogate the vicious cycle.[66] 
Target Blocking strategies 
Osteoclast function  
Bisphosphonates Small molecules 
RANKL Antibodies 
mTOR  Small molecules 
MET and VEGFR2 Tyrosine kinase inhibitors 
Cathepsin K  Small molecules 
Src Tyrosine kinase inhibitors 
LGR4 Antibodies 
Dock5 Small molecules 
Osteoblast function  
Wnt Small molecules, antibodies 
Endothelin Small molecules, antibodies 
Innate osteo-immunity  
CTLA-4  Antibodies 
PD-1 Antibodies 
PD-1 ligand Antibodies 
Bone matrix and micro-environment  
Nerve growth factor Antibodies 
Transforming growth factor く Antibodies 
 
Table 1: Summary pharmacological targets bone metastases. 
 
CLINICAL RESULTS OF TARGETED PHARMACOLOGIC INTERVENTION IN 
BONE METASTASES 
The previous paragraphs reviewed the different pathways and targets that are involved 
in normal and pathological bone remodeling and the interactions between bone and 
tumourcells (table 1). In the following sections a summary is provided of the main body 
of clinical evidence that provide the basis for the clinical use of agents that target these 
pathways. 
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Bisphosphonates 
Prevention of skeletal related events (SRE) in bone metastatic disease 
The benefits of bisphosphonate treatment has been evaluated in many malignancies, 
showing meaningful reductions in the risk of developing skeletal related events (SRE) 
in patients with multiple myeloma, or bone metastases from breast cancer, prostate 
cancer, and other solid tumors. While many bisphosphonates exist with some 
differences between their clinical use, zoledronic acid is probably the best studied 
molecule and carries the broadest label as it can be used for the prevention of SREs 
in all previously mentioned patient groups. 
Prevention of disease progression and death 
Based on tempting preclinical observations, zoledronic acid was also tested in an 
adjuvant setting in patients receiving curative treatment for breast cancer. Intriguingly, 
in post-menopausal women or when combined with ovarian suppression, the addition 
of zoledronic acid to endocrine treatment improved disease outcomes.[67, 68] In 
contrast, in patients receiving adjuvant chemotherapy after curative local treatment 
(AZURE trial), there was overall benefit in overall survival (HR 0.85; CI 95% 0.72-
1.01), but only in the subgroup of post-menopausal women.[69] This suggests that the 
interplay between bone and cancer may be dependent on the endocrine milieu (and 
more particular estrogen levels), opening up an entirely new direction of research. 
RANKL inhibitors 
Prevention of skeletal related events (SRE) in bone metastatic disease 
After the identification of RANKL as a potentially important therapeutic target in bone 
disease, the monoclonal anti-RANKL antibody denosumab was evaluated in a large 
number of clinical trials. In the setting of preventing SREs in bone metastatic disease 
denosumab has shown equal or superior efficacy compared to the bisphosphonate 
zoledronic acid. Firstly, a randomized control trial in advanced breast cancer patients 
(n=1026) comparing denosumab (120 mg SC/ 4 weeks) with zoledronic acid (4 mg IV/ 
4 weeks) favoured denosumab, when comparing the time to first (HR 0.82; 95% CI 
0.71-0.95) and subsequent (HR 0.77; 95% CI 0.66-0.89) SRE.[70] Also, in metastatic 
prostate cancer patients (n=1904) denosumab prolonged (HR 0.82; 95% CI 0.71-0.95) 
the time until first on study SRE compared with zoledronic acid.[71] Finally, in two 
randomized trials in multiple myeloma and solid tumours other than prostate and 
breast cancer, denosumab was found to be noninferior to zoledronic acid.[72, 73] 
Prevention of disease progression and death 
Having proven efficacy in the bone metastatic setting, several clinical trials have 
studied the potential of denosumab to prevent or delay the occurrence of bone 
metastases. In a large phase 3 randomized placebo controlled trial in men with 
castration resistant prostate cancer and unfavourable PSA kinetics (n=1432), 
denosumab (120 mg/ 4 weeks) increased bone metastasis free survival (HR 0.85; 95% 
CI 0.73-0.98) and delayed the time to first bone metastasis (HR 0.84; 95% CI 0.71-
0.98) compared to placebo. However, these positive results have not led to registration 
for this indication because of concerns of the risk of developing osteonecrosis of the 
jaw.[74] In postmenopausal women with breast cancer (n=3420) receiving adjuvant 
denosumab (60 mg SC/ 6 months) not only delayed the time to first clinical fracture 
(HR 0.50; 95% CI 0.39-0.65), but also improved disease-free survival (HR 0.82; 95% 
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CI 0.69-0.98) compared with placebo, mirroring the results seen with zoledronic acid 
in this setting.[75, 76] Finally, the D-CARE study recruited women with early stage 
breast cancer and randomized between denosumab (120 mg SC/ 3-4 weeks 6 times 
+ 120 mg SC/ 3 months for 54 months) and placebo given as adjuvant therapy together 
with chemotherapy. No benefit in the time to first bone metastases could be 
demonstrated with denosumab (HR 0.82; 95% CI 0.66-1.02), even though some 
secondary endpoints favoured the denosumab arm.[77] 
mTOR inhibitors 
Adding the mTOR inhibitor everolimus to the aromatase inhibitor exemestane in 
patients with advanced breast cancer improves outcomes compared to exemestane 
treatment alone. Interestingly, analyses of the profiles of bone turnover markers (e.g. 
bone-specific alkaline phosphatase, amino-terminal propeptide of type 1 collagen, and 
C-terminal cross-linking telopeptide of type 1 collagen) during treatment showed 
profound beneficial effects on disease progression in bone.[78] However, no further 
clinical development was performed specifically looking at the effects of everolimus on 
bone metastases in other cancers. 
MET and VEGFR2 inhibitors 
The results of an early phase II trial with cabozantinib in advanced prostate cancer 
looked extremely promising. Indeed, in a randomized controlled trial in castration-
resistant prostate cancer patients (n=171) a prolonged progression free survival in the 
cabozantinib (100 mg/day) treatment arm was seen compared to placebo (HR 0.12; 
p<0.001).[79] Unfortunately these results could not be confirmed in the pivotal phase 
3 trial (COMET-1) (n=1028) showing similar overall survival with cabozantinib or 
placebo (HR 0.90; 95% CI 0.76-1.06). Intriguingly, spectacular bone scan responses 
were seen with cabozantinib treatment (42% vs 3%, p= 0.001) as well as benefit in 
radiographic progression-free survival (HR 0.48; 95% CI 0.40-0.57).[80] 
These conflicting results highlight the crucial importance of understanding the 
mechanism of action of novel targeted agents in order to correctly interpret the results 
of imaging techniques including bone scintigraphy. Indeed, the highly specific effects 
of these treatments can lead to unexpected behaviour. Given the observed 
discrepancies between scintigraphic and clinical response, it was hypothesized that 
cabozantinib could interfere with local bone metabolism and uncouple the tumourand 
bone interaction. This was indeed confirmed in an elegant preclinical study where 
fractures were imaged with 18F-NaF-PET/CT and 99mTc-MDP scintigraphy after 7 days 
of treatment with cabozantinib. Even though no fracture healing was observed by that 
time, there was a greatly reduced uptake of the radiopharmaceutical probably by direct 
inhibition of osteoblast function, even though the mechanism of action needs further 
elucidation.[81] 
Cathepsin K inhibitors 
The available clinical data suggest that odanacatib has a similar efficacy to 
bisphosphonates in osteoporosis to increase bone mineral density and decrease the 
risk of fragility fractures.[82] However, concerns over an increased risk for 
cardiovascular events have led to the discontinuation of the clinical development of 
this molecule. 
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Src inhibitors 
While dasatanib has been shown to have effects on bone metastases in patients with 
advanced breast cancer, this molecule has not been further studied in this setting. 
Indeed, in a small trial (n=25) patients were treated with dasatinib 100 mg daily and 
zoledronic acid 4mg IV at the start of the study. Partial response in bone was seen in 
23% and the clinical benefit rate was 36%.[83] 
Activin A inhibitors 
Activin A is a regulator of bone remodelling and promotes osteoclast development and 
differentiation. Sotatercept is a decoy receptor that binds activin A with very high 
affinity preventing the continued loss of bone in myeloma patients with osteolytic 
lesions. In an early-phase clinical trial in multiple myeloma patients (n=30) sotatercept 
treatment resulted in an increase in bone alkaline phosphatase levels, suggesting 
increased osteoblastic activity. Nevertheless, these initial results need to be 
interpreted cautiously.[84] 
CHALLENGES IN BONE METASTASES IMAGING AND TREATMENT RESPONSE 
As discussed in the previous paragraphs, the mechanisms driving bone metastatic 
disease are numerous and complex. Progress in understanding these regulatory 
pathways has paved the way to new therapeutic targets in use today and many others 
still being actively researched. However, this mechanistic complexity also challenges 
the imaging methods used to assess response to these novel treatment candidates, 
as illustrated by the case of cabozantinib and bone scintigraphy. Together with 
historical insights regarding the specificity of imaging findings and the impact of 
confounding phenomena such as flare reaction when assessing response highlight 
the importance of continued validation of our techniques when new treatments are 
introduced. Currently, no single imaging technique is consistently superior for the 
assessment of metastatic bone disease across all tumour types and clinical scenarios. 
As will be discussed in the next papers in this special issue, both improvements in 
hardware and the development of new radiotracers will be required to solve the current 
hurdles in assessing metastatic bone disease. 
CONCLUSIONS 
Our understanding of the pathways driving bone remodeling in health and disease has 
increased considerably over the last decades, and new fields of study (e.g. osteo-
immunology) are only on the verge of being discovered. These breakthroughs have 
already translated into meaningful new treatments for patients with bone metastatic 
cancer. However, important challenges remain before this condition will become 
curable. This is also mirrored by the challenges introduced by novel targeted agents 
on assessing response in bone using nuclear medicine imaging methods, which will 
benefit from the development of new radiotracers and techniques. 
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